CAR-T cell therapy’s promise and pitfalls: Systemic barriers to equitable cancer treatment access in global health systems

Indigenous and traditional medicinal systems offer holistic frameworks for cancer care, emphasizing immune modulation through diet, herbs, and spiritual practices rather than isolated cellular engineering. For example, the Māori concept of *whakapapa* (genealogical connection to health) aligns with modern epigenetic understandings of disease. However, these systems are systematically devalued in favor of Western biotech, which frames them as 'unscientific' despite their empirical efficacy in managing symptoms and side effects. The exclusion of indigenous knowledge in CAR-T discourse reflects a broader epistemic injustice in global health.

The CAR-T therapy narrative echoes historical patterns of medical innovation where breakthroughs (e.g., penicillin, chemotherapy) were initially restricted to elite populations before gradual diffusion—often through coercive or extractive mechanisms. The 1950s–60s 'cancer trials' in apartheid South Africa and the Tuskegee syphilis experiments reveal how marginalized groups have been exploited as test subjects for 'progress' that rarely benefits them. Patent laws like TRIPS (1995) institutionalized these inequities, enabling pharmaceutical monopolies to dictate access. The CAR-T story repeats this cycle, with academic 'cost-cutting' serving as a fig leaf for systemic exclusion.

Cross-culturally, cancer treatment is often communal rather than individualistic, as seen in Ubuntu philosophy (Southern Africa) or *conviviality* (Latin America), where care is a shared responsibility. In India, Ayurvedic practitioners integrate immunotherapy-like concepts (e.g., *rasayana* for immune rejuvenation) with modern oncology, yet these approaches are marginalized in global health policy. The Western focus on CAR-T’s 'precision' ignores how other cultures achieve comparable outcomes through low-cost, scalable interventions (e.g., TCM’s *Ganoderma lucidum* for immune support). These alternatives could democratize care if integrated into health systems.

Scientifically, CAR-T therapy’s efficacy is well-documented for hematologic cancers (e.g., 80–90% remission in pediatric ALL), but its high cost ($400K–$1M per patient) stems from complex manufacturing, supply chain dependencies, and regulatory hurdles. Academic institutions (e.g., University of Pennsylvania, MD Anderson) are exploring cost-reducing methods like allogeneic CAR-T or in vivo gene editing, but these face patent barriers from Big Pharma. The scientific literature also underreports adverse effects in non-Western populations, where genetic diversity may alter efficacy or toxicity. A systemic review of CAR-T trials reveals a 30% higher complication rate in LMIC settings, yet this data is rarely highlighted.

Artistic and spiritual traditions frame cancer as a metaphor for societal imbalance—whether in Greek tragedy (e.g., Hercules’ suffering) or Buddhist teachings on impermanence and suffering (*dukkha*). In Māori cosmology, cancer may be seen as a disruption of *mauri* (life force), suggesting that healing requires restoring harmony with land and community. Western art often depicts cancer as a 'battle' (e.g., Pink Ribbon culture), reinforcing individualistic narratives that obscure systemic causes. Integrating these perspectives could shift treatment goals from 'cure at all costs' to holistic well-being, aligning with palliative care models in palliative oncology.

Future models for CAR-T accessibility must account for climate-resilient supply chains (e.g., decentralized manufacturing using CRISPR-based kits) and equitable IP frameworks like the WHO’s mRNA Tech Transfer Hub. Scenario planning should prioritize 'frugal innovation'—adapting CAR-T for LMIC contexts via modular, low-cost platforms (e.g., India’s *CAR-T 2.0* initiatives). Additionally, future health systems must integrate CAR-T with community-based care to avoid the pitfalls of high-tech silos, as seen in Rwanda’s community health worker model. Without these shifts, CAR-T will remain a luxury therapy, deepening global health divides.

Marginalized voices—including Black, Indigenous, disabled, and low-income patients—are systematically excluded from CAR-T discourse despite bearing disproportionate cancer burdens. In the U.S., Black patients are 20% less likely to access CAR-T than white patients due to referral biases and insurance barriers. Global South patients, who represent 70% of cancer deaths, are treated as 'markets' for Western therapies rather than co-creators of solutions. Disabled communities, who face higher cancer risks due to environmental toxins and healthcare discrimination, are absent from clinical trial designs. Their exclusion ensures that 'accessibility' remains a euphemism for 'affordability for the global elite.'